Search results for "Unstable angina"

showing 10 items of 80 documents

[Relationship of C-reactive protein levels with angiographic findings and markers of necrosis in non-ST-segment elevation acute coronary syndrome].

2004

The mechanism responsible for elevated C-reactive protein levels (inflammation of the ruptured atherosclerotic plaque or myocardial necrosis) in acute coronary syndromes is controversial. The aim of this study was to investigate the relationship between C-reactive protein levels and angiographic complexity of the culprit lesion and troponin elevation in patients with non-ST elevation acute coronary syndromes.The study group consisted of 125 patients with single-vessel disease. Troponin-I and C-reactive protein were measured, and the complexity of the culprit lesion was analyzed (TIMI flow and thrombus). Information on age, sex, smoking habit, hypertension, hypercholesterolemia and diabetes …

Malemedicine.medical_specialtyAcute coronary syndromeCoronary DiseaseCoronary AngiographyElectrocardiographyRisk FactorsInternal medicineDiabetes mellitusmedicineST segmentHumansThrombusbiologyRupture SpontaneousUnstable anginabusiness.industryC-reactive proteinTroponin IGeneral MedicineSyndromeMiddle Agedmedicine.diseaseTroponinC-Reactive ProteinAcute Diseasebiology.proteinCardiologyFemalebusinessTIMIBiomarkersRevista espanola de cardiologia
researchProduct

Resistin, acute coronary syndrome and prognosis results from the AtheroGene study

2006

Resistin, an adipocyte and macrophage derived cytokine, causes insulin resistance and glucose intolerance. We investigated the impact of resistin as a diagnostic marker in patients with acute coronary syndrome and its prognostic value for future cardiovascular events.Resistin levels were determined in 1153 patients with stable angina (SAP), 380 patients with unstable angina, 278 patients with non-ST-elevation myocardial infarction (NSTEMI) and 111 patients with ST-elevation myocardial infarction (STEMI). All patients have been followed up for a median follow-up of 2.6 years. During follow-up, 70 patients died from cardiovascular causes.Compared to SAP, resistin levels (5.1 ng/mL in SAP) wer…

Malemedicine.medical_specialtyAcute coronary syndromeMyocardial InfarctionCoronary DiseaseAngina PectorisCoronary artery diseaseImpaired glucose toleranceAnginaElectrocardiographyRisk FactorsInternal medicineHumansMedicineResistinAngina Unstablecardiovascular diseasesMyocardial infarctionRisk factorAgedbusiness.industryUnstable anginaSyndromeMiddle AgedPrognosismedicine.diseaseLipidsSurgeryAcute DiseaseCardiologyFemaleResistinInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersAtherosclerosis
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina

2006

SummaryApplication of clopidogrel before percutaneous coronary intervention in patients with acute coronary syndrome reduces the risk of cardiac events. Clopidogrel administration before surgery increases bleeding complications after CABG. Therefore, the antithrombotic effect of the low-dose combination of clopidogrel and aspirin was investigated in an in vivo pig model of coronary artery thrombus formation with cyclic flow reductions. The platelet inhibitory effect was determined by platelet aggregation and CFR, according to the methodology described by Folts. CFR were initiated by endothelial damage and placement of a constrictor around the LAD. 30 min after CFR were established, clopidog…

Malemedicine.medical_specialtyAcute coronary syndromeTiclopidinePlatelet AggregationSwinemedicine.medical_treatmentAnginaInternal medicineAntithromboticmedicineAnimalsPlateletAngina Unstablecardiovascular diseasesAspirinAspirinbusiness.industryUnstable anginaCoronary ThrombosisPercutaneous coronary interventionHematologymedicine.diseaseClopidogrelClopidogrelDisease Models AnimalAcute DiseaseCardiologyDrug Therapy CombinationbusinessPlatelet Aggregation Inhibitorscirculatory and respiratory physiologymedicine.drugThrombosis and Haemostasis
researchProduct

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the A…

2007

Summary. Background: Tissue factor (TF) and its specific inhibitor, tissue factor pathway inhibitor (TFPI), are important contributors to the initiation of the coagulation process. Objectives: To compare plasma levels of soluble TF (sTF) and free-TFPI (f-TFPI) between patients with stable angina pectoris (SAP) and acute coronary syndrome (ACS) and to assess the impact of the two variables on long-term prognosis. Patients/methods: Patients with SAPs (n = 1146) and acute coronary syndrome (n = 523) from the AtheroGene study were included and followed for 2.3 years. Because of the strong impact of unfractionated heparin (UFH) on f-TFPI levels, but not on sTF levels, patients having received UF…

Malemedicine.medical_specialtyAcute coronary syndromeTime FactorsLipoproteinsMyocardial InfarctionRisk AssessmentSeverity of Illness IndexAngina PectorisThromboplastinCoronary artery diseaseCohort StudiesTissue factor pathway inhibitorPredictive Value of TestsInternal medicineGermanymedicineHumansMyocardial infarctionProspective StudiesAgedProportional Hazards ModelsUnstable anginabusiness.industryHazard ratioCoronary StenosisHematologySyndromeMiddle Agedmedicine.diseasePrognosisThrombosisCardiovascular DiseasesCardiologyFemalebusinessBiomarkersBlood drawingFollow-Up StudiesJournal of thrombosis and haemostasis : JTH
researchProduct

An Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes. From Large Trials to the Real World

2004

Introduction and objectives We report the impact on prognosis of an invasive strategy used at our center for non-ST-segment elevation acute coronary syndrome. Patients and method We analyzed 504 consecutive patients with typical chest pain, electrocardiographic changes or increased troponin I serum values, who were divided into 2 cohorts: a ) conservative group, 272 patients admitted between October 2001 and September 2002 and managed with a conservative strategy, and b ) invasive group, 232 patients admitted between October 2002 and September 2003 for whom an invasive strategy was recommended. We recorded major events (death or reinfarction) and minor events (readmission or need for post-d…

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentMyocardial InfarctionChest painRevascularizationAngioplastyInternal medicinemedicineHumansST segmentAngina UnstableAgedUnstable anginabusiness.industryIncidence (epidemiology)AngioplastyHazard ratioSyndromeGeneral MedicinePrognosismedicine.diseaseSurgeryAcute DiseaseCardiologyFemalemedicine.symptombusinessRevista Española de Cardiología (English Edition)
researchProduct

Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion.

1995

Studies showed that endothelin-1 (ET-1) was increased in the acute myocardial infarction (AMI). Experimental studies reported that captopril was able to reduce ET-1 secretion, and that ET-1 was increased during reperfusion. This study was aimed to verify if captopril was able to reduce plasma ET-1 during thrombolysis in AMI. Seventy-three patients, hospitalized for suspected AMI within 4 h from the onset of symptoms suitable for thrombolysis (1st episode), Killip class 1-2, were randomized (double blind) into two groups: group 1 (37 pts), 8 F/29 M, received captopril, 6.25 mg, orally 15 min before thrombolysis. Group 2: (36 pts) 8 F/28 M, received placebo before thrombolysis. All patients m…

Malemedicine.medical_specialtyCaptoprilTime Factorsmedicine.medical_treatmentMyocardial InfarctionAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressureMyocardial ReperfusionPlaceboAnginaPlacebosElectrocardiographyDouble-Blind MethodHeart RateInternal medicineFibrinolysismedicineHumansThrombolytic TherapyMyocardial infarctionAngina UnstableCreatine KinaseKillip classbusiness.industryUnstable anginaEndothelinsCaptoprilThrombolysismedicine.diseaseRecombinant ProteinsSurgeryIsoenzymesTissue Plasminogen ActivatorCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational journal of cardiology
researchProduct

Clinical predictors of unstable coronary lesion morphology.

1995

We evaluated prospectively clinical and angiographic data in 400 patients, 200 with unstable and 200 with stable angina in order to determine which clinical markers could reliably predict unstable coronary artery lesions. Comparison of the angiogram of 200 patients with unstable and 200 with stable angina revealed a high-grade lesion (42% vs 23%, P < 0.0001), complex lesion morphology (49% vs 20%, P < 0.0001) and thrombus-containing lesions (7% vs 1%, P = 0.006) as typical findings in patients with unstable angina. A high-grade lesion and/or complex lesion (including thrombotic lesions but excluding total occlusion) was found in 61% of unstable and 34% of stable patients (P < 0.0001). Clini…

Malemedicine.medical_specialtyCoronary AngiographyAngina PectorisLesionAnginaElectrocardiographyInternal medicinemedicineHumanscardiovascular diseasesAngina UnstableProspective StudiesProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryUnstable anginaOdds ratioMiddle Agedmedicine.diseasemedicine.anatomical_structureAngiographyMultivariate AnalysisCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessElectrocardiographyArteryForecastingEuropean heart journal
researchProduct

Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease.

1996

To investigate whether circulating endothelin-1 (Et-1) may be related to the increased incidence and severity of ischaemic heart disease in type 2 diabetes mellitus, we compared the concentrations in type 2 diabetic patients and in non-diabetic patients with coronary artery disease (CAD) angiographically documented. Plasma levels of Et-1 were determined in 34 type 2 diabetic patients with CAD (16 with stable angina, 6 with unstable angina, 12 with previous myocardial infarction) and in 19 nondiabetic patients with CAD (4 with stable angina, 5 with unstable angina, 10 with previous myocardial infarction). Fifteen diabetic patients without CAD and 9 healthy volunteers served as control subjec…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMyocardial InfarctionMyocardial IschemiaBlood PressureAngina PectorisCoronary artery diseaseEndocrinologyReference ValuesDiabetes mellitusInternal medicineInternal MedicinemedicineHumanscardiovascular diseasesMyocardial infarctionEndothelial dysfunctionAgedAnalysis of VarianceEndothelin-1business.industryUnstable anginaIncidenceType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseEndothelin 1Diabetes Mellitus Type 2CardiologyFemaleComplicationbusinessActa diabetologica
researchProduct

Prognostic value of exercise myocardial scintigraphy in patients with coronary chronic total occlusions.

2010

Objectives: To evaluate the prognostic value of exercise myocardial scintigraphy in patients undergoing incomplete revascularization by means of percutaneous coronary intervention (PCI) with at least a residual chronic total occlusion (CTO) left untreated. Methods: Of 569 consecutive patients with multivessel disease undergoing myocardial scintigraphy after incomplete revascularization by PCI between March 1997 and December 2004, 126 (79% male, 64 ± 10 years) with ≥ 1 residual CTO fulfilled the eligibility criteria and entered in the study. Hard events defined as cardiac death and myocardial infarction, soft events defined as incidence of unstable angina and PCI procedures, and their compos…

Malemedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentCoronary AngiographyRisk AssessmentMyocardial perfusion imagingOrganophosphorus CompoundsPredictive Value of TestsInternal medicineCoronary CirculationmedicinescintigraphyHumanscto.Radiology Nuclear Medicine and imagingMyocardial infarctionAngioplasty Balloon CoronaryAgedProportional Hazards ModelsTomography Emission-Computed Single-PhotonEjection fractionexercisemedicine.diagnostic_testbusiness.industryUnstable anginaIncidence (epidemiology)Myocardial Perfusion ImagingPercutaneous coronary interventionmyocardialOrganotechnetium CompoundsMiddle Agedmedicine.diseasePrognosisCoronary OcclusionConventional PCIChronic DiseaseCardiologyExercise TestFemaleRadiopharmaceuticalsCardiology and Cardiovascular MedicinebusinessPerfusionFollow-Up StudiesJournal of interventional cardiology
researchProduct